Data from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom
NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts\u2019 (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world
A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with \u00a32.5 million funding from UK Research and Innovation (UKRI)
The University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK
From a small discovery to producing at scale, photojournalist David Levene documents the groundbreaking work of the scientists of Oxford University during the development of a vaccine which is now poised for approval by medicines regulators
Data from the National COVID-19 Infection Survey, done in partnership between the University of Oxford, the Office of National Statistics, Public Health England, University of Manchester and the Wellcome Trust, has revealed detailed characteristics of England\u2019s coronavirus pandemic, including which factors have contributed most to case numbers over different phases and the prevalence of asymptomatic infections.
Today, the University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
This year's Young Scientists of the Year 2020 events for outstanding Year 13 science students in Oxfordshire and Buckinghamshire took place on Wednesday 19 November together with their families and teachers attending via zoom.
The University of Oxford has joined forces with Thermo Fisher Scientific, the world leader in serving science, to ramp up the university\u2019s capacity to deliver COVID-19 testing data.
Kenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine. Following the necessary approvals from regulators, as well as the national ministry of health, and Kilifi county, the first volunteers for the trial have recently received their vaccinations.
Following the announcement in June of a new philanthropic relationship between Bvlgari and the University of Oxford, Bvlgari\u2019s donation in support of DPhil students in vaccine research benefits two exceptional students, appointed as the first cohort of Bvlgari Scholars. The Jenner Institute welcomes students Cameron Bissett and Rebecca Makinson this month for the start of their DPhil courses, after demonstrating remarkable academic potential and merit in the field of vaccine-related immunology.
Thousands of lives could be saved by measuring the strength of the antibody response in those who have had the virus and how long their immunity may last for. Professor Paul Klenerman and his team at the University of Oxford have partnered with Oxford University Hospitals NHS Foundation Trust (OUH) to test thousands of healthcare workers.
Prof Chris Holmes, The Alan Turing Institute\u2019s Programme Director of Health and Medical Science, and Professor of Biostatistics at the Nuffield Department of Medicine, said: \u201cThe Turing is delighted to be playing a pivotal role in supporting the JBC by working to build an alliance with the RSS and academic experts to provide new insights in the evolving fight against COVID-19. In doing so, we will strengthen knowledge across the wider public health ecosystem.\"
New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as \u2018immunoassays\u2019), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.
Scientists from the University of Oxford\u2019s Nuffield Department of Medicine have today published their evaluation of LamPORE, a novel diagnostic platform for detecting SARS-CoV-2 RNA. It combines loop-mediated isothermal amplification with nanopore sequencing. This technology has the potential to analyse thousands of samples per day on a single instrument.
![\"\"](\"https://www.cbf.ox.ac.uk/news/national-survey-reveals-big-reductions-in-covid-19-infections-with-single-dose-of-oxford-az-and-pfizer-vaccines/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n